Die Gicht richtig diagnostizieren und behandeln

Irreversible Folgeschäden vermeiden
  • Matthias Witt


Die Gicht zählt zu den häufigen Erkrankungen und ihre Inzidenz und Prävalenz nehmen weiter zu. Durch die Assoziation der Gicht mit Erkrankungen des metabolischen Syndroms sowie mit kardiovaskulären Erkrankungen geht die Gicht oft mit einer erheblichen Krankheitslast einher. Durch frühzeitige Diagnose und konsequenten Einsatz der verfügbaren Therapeutika, Lebensstilmodifikationen und Patientenschulung kann die Gicht im Prinzip geheilt werden. Irreversible Folgeschäden an Gelenken lassen sich dadurch verhindern.


Gicht Harnsäure Allopurinol Febuxostat Canakinumab 

Diagnosing and treating gout correctly

Prevention of irreversible damage


Gout is one of the more frequent diseases and the incidence and prevalence are increasing. Due to the association of gout with diseases of the metabolic syndrome and with cardiovascular diseases, gout is often accompanied by a substantial burden of disease. Gout can principally be cured by early diagnosis and consistent use of the available therapeutic drugs, life style modifications and patient education. The implementation of these measures can prevent irreversible damage to the joints.


Gout Uric acid Allopurinol Febuxostat Canakinumab 



Der Autor erklärt, dass er sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen leiten ließ. Der Autor gibt an, dass kein Interessenkonflikt besteht.


  1. 1.
    Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73(8):1470–6.CrossRefGoogle Scholar
  2. 2.
    Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67(7):960–6.CrossRefGoogle Scholar
  3. 3.
    Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–46.Google Scholar
  4. 4.
    Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447–61.CrossRefGoogle Scholar
  5. 5.
    Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.CrossRefGoogle Scholar
  6. 6.
    Kiltz U, Alten R, Fleck M, Kruger K, Manger B, Muller-Ladner U, et al. [Full version of the S2e guidelines on gouty arthritis: Evidence-based guidelines of the German Society of Rheumatology (DGRh)]. Z Rheumatol. 2016;75 Suppl 2:11–60.CrossRefGoogle Scholar
  7. 7.
    Ankli B, Kyburz D, Hirschmann A, Hugle T, Manigold T, Berger CT, et al. Calcium pyrophosphate deposition disease: a frequent finding in patients with long-standing erosive gout. Scand J Rheumatol. 2017:1–4.Google Scholar
  8. 8.
    Sivera F, Andres M, Carmona L, Kydd AS, Moi J, Seth R, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328–35.CrossRefGoogle Scholar
  9. 9.
    Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. Rheumatology (Oxford). 2007;46(7):1116–21.CrossRefGoogle Scholar
  10. 10.
    Pineda C, Amezcua-Guerra LM, Solano C, Rodriguez-Henriquez P, Hernandez-Diaz C, Vargas A, et al. Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study. Arthritis Res Ther. 2011;13(1):R4.CrossRefGoogle Scholar
  11. 11.
    Naredo E, Uson J, Jimenez-Palop M, Martinez A, Vicente E, Brito E, et al. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis. 2014;73(8):1522–8.CrossRefGoogle Scholar
  12. 12.
    Das S, Ghosh A, Ghosh P, Lahiri D, Sinhamahapatra P, Basu K. Sensitivity and specificity of ultrasonographic features of gout in intercritical and chronic phase. Int J Rheum Dis. 2017;20(7):887–93.CrossRefGoogle Scholar
  13. 13.
    Johnson TR, Weckbach S, Kellner H, Reiser MF, Becker CR. Clinical image: Dual-energy computed tomographic molecular imaging of gout. Arthritis Rheum. 2007;56(8):2809.CrossRefGoogle Scholar
  14. 14.
    Jacques T, Michelin P, Badr S, Nasuto M, Lefebvre G, Larkman N, et al. Conventional Radiology in Crystal Arthritis: Gout, Calcium Pyrophosphate Deposition, and Basic Calcium Phosphate Crystals. Radiol Clin North Am. 2017;55(5):967–84.CrossRefGoogle Scholar
  15. 15.
    Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789–98.CrossRefGoogle Scholar
  16. 16.
    Billy CA, Lim RT, Ruospo M, Palmer SC, Strippoli GFM. Corticosteroid or Nonsteroidal Antiinflammatory Drugs for the Treatment of Acute Gout: A Systematic Review of Randomized Controlled Trials. J Rheumatol. 2017.Google Scholar
  17. 17.
    Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–8.CrossRefGoogle Scholar
  18. 18.
    Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs. 2011;71(11):1413–39.CrossRefGoogle Scholar
  19. 19.
    Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–48.CrossRefGoogle Scholar
  20. 20.
    So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.CrossRefGoogle Scholar
  21. 21.
    Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis – data from a prospective observational cohort study. Arthritis Res Ther. 2011;13(2):R66.CrossRefGoogle Scholar
  22. 22.
    Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529–36.CrossRefGoogle Scholar
  23. 23.
    Ramasamy SN, Korb-Wells CS, Kannangara DR, Smith MW, Wang N, Roberts DM, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf. 2013;36(10):953–80.CrossRefGoogle Scholar
  24. 24.
    Becker MA, Schumacher HR, Jr., Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–61.CrossRefGoogle Scholar
  25. 25.
    Taylor TH, Mecchella JN, Larson RJ, Kerin KD, Mackenzie TA. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med. 2012;125(11):1126–34 e7.CrossRefGoogle Scholar
  26. 26.
    Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C, Group RS. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016;75(6):1074–80.CrossRefGoogle Scholar
  27. 27.
    Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711–20.CrossRefGoogle Scholar
  28. 28.
    Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1):123.CrossRefGoogle Scholar
  29. 29.
    Anzai N, Jutabha P, Amonpatumrat-Takahashi S, Sakurai H. Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies. Clin Exp Nephrol. 2012;16(1):89–95.CrossRefGoogle Scholar
  30. 30.
    Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, et al. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis. 2015;66(6):945–50.CrossRefGoogle Scholar
  31. 31.
    Stamp LK, O’Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412–21.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Rheumazentrum Bad Aibling – ErdingErdingDeutschland

Personalised recommendations